SpyGlass Pharma Q2 net loss $19.9M; cash $234.2M; Phase 3 enrollment on track

SpyGlass Pharma, Inc.

Net loss of $19.9M ($0.59 per share) vs $8.7M ($3.81) in Q2 2025.
Cash, cash equivalents and short-term investments of $234.2M expected to fund operations through 2028.
Enrollment in Phase 3 registrational trials of BIM-IOL System on track for completion in 2027.
BIM-DRS first-in-human trial expected to start in H2 2026.
Appointed Mike Pinder as VP Marketing; new CPT code for reimbursement pathway.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.